Serenity and Relief for Patients with Anxiety

Introducing the first prescription digital therapy designed to treat Generalized Anxiety Disorder (GAD) and Panic Disorder (PD)

reVIVETM: FOR GENERALIZED ANXIETY DISORDER and PANIC DISORDER

Pear Therapeutics has developed reVIVETM, a mobile medical application to be used in combination with medication for treating GAD and PD

Patient-Facing Smartphone Application  + Benzodiazepine Medication

WHAT IS reVIVETM?

  • reVIVETM offers an innovative method for treating GAD, a psychiatric disease characterized by long-lasting anxiety not focused on a specific object or situation, as well as PD, a disease in which debilitating anxiety and fear can arise without reasonable cause1
  • reVIVETM utilizes a combination of assessments, dosing and therapeutic paradigms to treat anxiety conditions
  • By tailoring the digital therapy to the pharmacokinetics of the benzodiazepine, reVIVETM is able to enhance clinical outcomes
1www.nimh.nih.gov/health/topics/anxiety-disorders

reVIVETM AS A TREATMENT TOOL FOR GAD and PD

reVIVETM produces a significant decrease in self-assessed measures of anxiety in patients diagnosed with GAD

  • A randomized controlled trial, involving 25 GAD patients, was carried out over 8 sessions and included both relaxation and exposure techniques.
  • The following psychometric questionnaires were administered to each patient before and after treatment:
    • Beck Anxiety Inventory (BAI) – a 21-item scale measuring cognitive, behavioral and physiological symptoms of anxiety
    • Hamilton Anxiety Rating Scale (HAM-A) – a 14-item scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety)
    • State-Trait Anxiety Inventory Form (STAI) – a 2-scale questionnaire including 20 items each that differentiates between the temporary condition of “state anxiety” (STAY-Y1) and the more general and long-standing quality of “trait anxiety” (STAY-Y2)
  • Mean scores from psychometric questionnaires significantly decreased from pre-treatment to post-treatment in BAI (26.65 to 14.50; p<0.05) and STAI  (54.15 to 45.50; p<0.05).  HAM-A mean scores decreased from 25.00 to 15.00 (p<0.11).

 

Repetto et al.  Pers and Ubiq Computing.  2011.

For more information, please contact us

Contact Us

*reVIVETM not yet available for sale in the United States